American Society of Hematology Annual Meeting & Exposition

Combining ibrutinib with rituximab resulted in improved 2-year progression-free survival among elderly patients with previously untreated diffuse large B-cell lymphoma.

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Data from a recent analysis demonstrated that more than one in five people experienced depression or anxiety, either before or not long after receiving a blood cancer diagnosis, highlighting the need for further mental health screening in these individuals.

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

A recent study analyzed nurse and patient preference when it came to the administration of rituximab in patients with blood cancer.